Patent · US Active

Triazene compounds for the treatment of cancer

US8034797B2 · kind B2 · utility

0Cited by

0References

8Claims

0Family size

Assignee

Trin Therapeutics GmbH · DE

Inventors

Rudolf Reiter · Graz, AT
Jochen Kalbe · Leichlingen, DE
Heinz Forster · Wuppertal, DE

Key dates

Filing date	Jul 3, 2008
Grant date	Oct 11, 2011
Priority date	—
Expiry date	Jan 31, 2029

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D233/64
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The present invention relates to novel triazene compounds, to a process for their preparation, to pharmaceutical compositions comprising them, and to the use thereof in the treatment of cancer diseases in humans. The novel triazene compounds are distinguished, as compared with the known triazene compounds, by improved activity while at the same time having reduced toxicity, that is to say by fewer side-effects.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.